{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"12700","value":"23700"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"title":"Cycle 3 Day 1"},{"categories":[{"measurements":[{"comment":"Standard deviation could not be estimated for Cycle 5 Day 1 as insufficient number of participants were available for analysis.","groupId":"OG000","spread":"NA","value":"4630"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"Cycle 5 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Participants were not available for analysis at Cycle 3 Day 1, hence no PK data was collected and analyzed for this timepoint.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with stages I to III CTCL were treated with E7777 9 mcg/kg by IV infusion over 60 minutes on 5 consecutive days in 21-day cycles for up to 8 cycles or disease progression or unacceptable toxicity in Lead-in part and in Main study part and were presented together here, as planned.","id":"OG000","title":"Main Study Part: E7777 9 mcg/kg"}],"paramType":"MEAN","populationDescription":"Main study part PK analysis set included all participants from whom at least one quantifiable concentration of E7777 was observed at 9 mcg/kg dose (both Main Study and Lead-In). Here \"overall number of participants analyzed\" signifies participants who were evaluable for this outcome measure. Here \"number analyzed\" signifies participants who were evaluable for this outcome measure at given time points.","reportingStatus":"POSTED","timeFrame":"Cycles 1, 3 and 5 Day 1: Pre-dose up to 300 hours post-dose (Cycle length was 21 days)","title":"Main Study Part: Area Under the Curve From Time 0 to Time Infinity (AUC[0-inf]) of E7777","type":"SECONDARY","unitOfMeasure":"min*ng/mL"}